ETIDIOH - NEW

  Antiviral Res BESSONNE M, Morel J, Nevers Q, Groutsch J, et al Inhibition of influenza virus replication by artificial proteins (alphaReps) targeting its RNA-polymerase. Antiviral Res. 2025 Oct 21:106300. doi: 10.1016/j.antiviral.2025.106300. PubMed           Abstract available BMC Pediatr WONG K, Ducharme R, Murphy MSQ, Clarke AE, et al SARS-CoV-2 infection in pregnancy and infant outcomes in the first year of life: a retrospective cohort study. BMC Pediatr. 2025;25:842. PubMed           Abstract available MAGGIO ABR, Palomo S, Joye R, Huguet H, et al Reduced aerobic capacity in children with multisystem inflammatory syndrome in children (MIS-C) after PICU admission: a retrospective cohort study, 2020-2022. BMC Pediatr. 2025;25:835. PubMed           Abstract available Cell HICKMAN HD, Moutsopoulos NM Don't forget to floss! An innovative approach for vaccine del...

  Highlights •  Human antibody HB420 cross-reacts with neuraminidases from H3N2 and H5N1 •  HB420 engages the neuraminidase active site via a single Asp residue •  Germline HB420 is N2 specific but gains reactivity to N1 through somatic mutation •  HB420 provides in vivo protection against both H3N2 and H5N1 Summary The ongoing spread of highly pathogenic avian influenza H5N1 clade 2.3.4.4b virus in animals and its occasional spillover to humans have raised concerns about a potential H5N1 pandemic . Although recent studies have shown that pre-existing human antibodies can recognize H5N1 neuraminidase , the molecular basis of how this cross-reactivity develops remains poorly understood. In this study, we used a phage display antibody library derived from 245 healthy donors to isolate an antibody , HB420, that cross-reacts with neuraminidases of human H3N2 and avian H5N1 clade 2.3.4.4b viruses and confers protection in vivo . Cryogenic electron microscopy analysis...

  Antiviral Res PATEL MC, Nguyen HT, Mishin VP, Pascua PNQ, et al Antiviral susceptibility monitoring: testing algorithm, methods, and findings for influenza season, 2023-2024. Antiviral Res. 2025 Oct 11:106299. doi: 10.1016/j.antiviral.2025.106299. PubMed           Abstract available ZHU C, Wang Z, Pan Z, Mai X, et al DMBT1 promotes SARS-CoV-2 infection and its SRCR-derived peptide inhibits SARS-CoV-2 infection. Antiviral Res. 2025 Sep 3:106269. doi: 10.1016/j.antiviral.2025.106269. PubMed           Abstract available TASHIMA R, Kuroda T, Nobori H, Miyagawa S, et al Ensitrelvir suppresses prolonged olfactory abnormalities derived from SARS-CoV-2 infection in hamsters. Antiviral Res. 2025 Sep 2:106270. doi: 10.1016/j.antiviral.2025.106270. PubMed           Abstract available BMC Pediatr WU LE, Wei JY, Lin ZH, Li HC, et al Clinical characteristics of children with ...

  Abstract The SARS outbreak and influenza A(H5N1) infections (2003–2004) prompted WHO to establish a global influenza antiviral stockpile , enabling rapid distribution to 72 countries during the 2009 A(H1N1) pandemic. To improve access in low- and middle-income countries, WHO added antivirals to the WHO Model List of Essential Medicines and included them in the Prequalification Programme . The 2011 Pandemic Influenza Preparedness Framework refined strategies for equitable access and rapid response. Lessons from COVID-19 led to a new WHO-led mechanism—the Interim Medical Countermeasures Network (i-MCM-net)— which supports integrated supply chains, real-time data sharing, research and development, and equitable access. WHO continues to emphasise equity and global solidarity , highlighting the need for accessible, effective, and affordable antivirals alongside vaccines to protect vulnerable populations and mitigate the impact of future pandemics. Source: Journal of Infectious Disease...

  Abstract This supplement contains 17 articles addressing various aspects of advances in influenza therapeutics and related strategies (e.g., diagnostics, rapid access strategies , and resistance monitoring ) for preventing and treating seasonal, zoonotic, and pandemic influenza . In addition to briefly introducing each article, we highlight shortcomings in current use, knowledge gaps requiring further study, and therapeutics of interest entering or advancing in clinical development. Source: Journal of Infectious Diseases,  https://academic.oup.com/jid/article/232/Supplement_3/S169/8287899?login=false ____

  Abstract The antigenic relationship between Eurasian avian-like H1N1 swine influenza viruses (EA H1N1) and human pandemic 2009 H1N1 viruses (2009/H1N1) remains a critical question for influenza surveillance and vaccine efficacy . This study systematically investigated the antigenic differences between strains A/swine/Tianjin/312/2016 (TJ312, EA H1N1) and A/Guangdong-Maonan/SWL1536/2019 (GD1536, 2009/H1N1). Cross-hemagglutination inhibition (HI) assays revealed a significant antigenic disparity, with a 16-fold reduction in heterologous versus homologous HI titers . Comparative sequence analysis identified 22 amino acid differences across the five major antigenic sites (Sa, Sb, Ca1, Ca2, and Cb) of the HA1 subunit. Using reverse genetics , a panel of mutant viruses was generated. This study revealed that a single histidine (H)-to-asparagine (N) substitution at residue 128 (H3 numbering) in the Sa antigenic site acts as a primary determinant of antigenic variation , sufficient to ca...

  Ann Intern Med LE VU M, Matthes KL, Schneider EB, Moerlen A, et al Maternal Influenza-Like Illness and Neonatal Health During the 1918 Influenza Pandemic in a Swiss City. Ann Intern Med. 2025 Oct 7. doi: 10.7326/ANNALS-24-03796. PubMed           Abstract available Antiviral Res SCHRELL L, Scheibner D, Dickmanns A, Stegmann KM, et al Inhibitors of pyrimidine synthesis synergize with N4-hydroxycytidine to diminish influenza virus replication. Antiviral Res. 2025 Oct 3:106286. doi: 10.1016/j.antiviral.2025.106286. PubMed           Abstract available Epidemiol Infect VAN DER ROEST B, Fischer EAJ, Klinkenberg D, Bootsma MCJ, et al Phylodynamic inference suggests introductions as main driver of Mpox Clade II outbreak in 2022 in Slovenia. Epidemiol Infect. 2025;153:e115. PubMed           Abstract available WOLDEGIORGIS M, Bloomfield L, Korda R, Cadby G, et al Factors a...

  Am J Med WAHID L, Kwon T, Kreuziger LB, Kasthuri RS, et al Extended Thromboprophylaxis in Patients Hospitalized with COVID-19 at Time of Discharge is Not Associated with Improvement in Quality of Life. Am J Med. 2025;138:1464-1468. PubMed           Abstract available Biochem Biophys Res Commun ZHANG L, Li Y, Ye K, Wang P, et al Article I. metformin affects H1N1-induced apoptosis in lung epithelial cells by the miR-130a-5p-regulated PI3K/AKT signaling pathway. Biochem Biophys Res Commun. 2025;782:152526. PubMed           Abstract available J Gen Virol HA Y, Lee YH, Jo HS, Kwon TW, et al Susceptibility of different mouse strains to SARS-CoV-2 spike receptor-binding domain protein-induced lung inflammation: a comparative study. J Gen Virol. 2025;106. PubMed           Abstract available J Infect Dis GAILLET A, Layese R, Fourati S, Celante H, et al Clinical Phenotype...